To evaluate the risk of long-term tumour recurrence and progression in patients with low- and intermediate-risk NMIBCs, which could facilitate optimisation in the follow-up schedules.
A single-institution, retrospective analysis of 704 patients with primary TaG1, TaG2, T1G1, and T1G2 urothelial carcinomas of the bladder (UBS) without concomitant carcinoma in situ (CIS), treated with transurethral resection (TUR) was performed.